Similarly, BRAF/MEK inhibitors for those with stage III disease carrying an activating mutation in the BRAF V600 gene are currently approved for clinical use, based upon the results of the COMBI-AD study, in which the combination of dabrafenib and trametinib also led to improved outcomes compared to the placebo in patients undergoing adjuvant treatment after the surgical resection of stage IIIA to stage IIIC melanoma [15]. The gene discussed is MAP2K7; the disease is melanoma.